Takeda Pharmaceutical (TAK) Competitors

$16.58 -0.04 (-0.21%)

Closing price 03:59 PM Eastern

Extended Trading

$16.57 0.00 (-0.03%)

As of 07:29 PM Eastern

TAK vs. NVO, SNY, GSK, ARGX, and TEVA

Should you buy Takeda Pharmaceutical stock or one of its competitors? MarketBeat compares Takeda Pharmaceutical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Takeda Pharmaceutical include Novo Nordisk A/S (NVO), Sanofi (SNY), GSK (GSK), argenex (ARGX), and Teva Pharmaceutical Industries (TEVA). These companies are all part of the "pharmaceutical products" industry.

How does Takeda Pharmaceutical compare to Novo Nordisk A/S?

Takeda Pharmaceutical (NYSE:TAK) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Takeda Pharmaceutical has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market.

In the previous week, Novo Nordisk A/S had 34 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 50 mentions for Novo Nordisk A/S and 16 mentions for Takeda Pharmaceutical. Novo Nordisk A/S's average media sentiment score of 0.59 beat Takeda Pharmaceutical's score of 0.12 indicating that Novo Nordisk A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral
Novo Nordisk A/S	17 Very Positive mention(s)	8 Positive mention(s)	13 Neutral mention(s)	10 Negative mention(s)	2 Very Negative mention(s)	Positive

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Novo Nordisk A/S has a net margin of 37.23% compared to Takeda Pharmaceutical's net margin of 4.31%. Novo Nordisk A/S's return on equity of 63.31% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.31%	11.07%	5.49%
Novo Nordisk A/S	37.23%	63.31%	22.19%

Takeda Pharmaceutical pays an annual dividend of $0.50 per share and has a dividend yield of 3.0%. Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.9%. Takeda Pharmaceutical pays out 128.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Novo Nordisk A/S has higher revenue and earnings than Takeda Pharmaceutical. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	1.86	$1.27B	$0.39	42.50
Novo Nordisk A/S	$46.80B	4.23	$15.51B	$4.26	10.40

Novo Nordisk A/S has a consensus target price of $65.56, suggesting a potential upside of 47.93%. Given Novo Nordisk A/S's higher probable upside, analysts plainly believe Novo Nordisk A/S is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Novo Nordisk A/S	1 Sell rating(s)	18 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13

Summary

Novo Nordisk A/S beats Takeda Pharmaceutical on 17 of the 18 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to Sanofi?

Takeda Pharmaceutical (NYSE:TAK) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

Sanofi has a consensus price target of $51.00, suggesting a potential upside of 17.13%. Given Sanofi's higher probable upside, analysts plainly believe Sanofi is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47

Sanofi has a net margin of 16.95% compared to Takeda Pharmaceutical's net margin of 4.31%. Sanofi's return on equity of 13.39% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.31%	11.07%	5.49%
Sanofi	16.95%	13.39%	7.58%

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by insiders. Comparatively, 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Takeda Pharmaceutical pays an annual dividend of $0.50 per share and has a dividend yield of 3.0%. Sanofi pays an annual dividend of $1.77 per share and has a dividend yield of 4.1%. Takeda Pharmaceutical pays out 128.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Sanofi pays out 49.4% of its earnings in the form of a dividend. Sanofi is clearly the better dividend stock, given its higher yield and lower payout ratio.

Sanofi has higher revenue and earnings than Takeda Pharmaceutical. Sanofi is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	1.86	$1.27B	$0.39	42.50
Sanofi	$49.35B	2.15	$8.84B	$3.58	12.16

Takeda Pharmaceutical has a beta of -0.06, indicating that its stock price is 106% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

In the previous week, Takeda Pharmaceutical had 13 more articles in the media than Sanofi. MarketBeat recorded 16 mentions for Takeda Pharmaceutical and 3 mentions for Sanofi. Sanofi's average media sentiment score of 1.48 beat Takeda Pharmaceutical's score of 0.12 indicating that Sanofi is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sanofi	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sanofi beats Takeda Pharmaceutical on 16 of the 19 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to GSK?

GSK (NYSE:GSK) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

GSK has higher revenue and earnings than Takeda Pharmaceutical. GSK is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.37	$7.54B	$3.85	13.06
Takeda Pharmaceutical	$28.32B	1.86	$1.27B	$0.39	42.50

GSK has a net margin of 17.82% compared to Takeda Pharmaceutical's net margin of 4.31%. GSK's return on equity of 44.28% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.82%	44.28%	11.49%
Takeda Pharmaceutical	4.31%	11.07%	5.49%

GSK pays an annual dividend of $1.81 per share and has a dividend yield of 3.6%. Takeda Pharmaceutical pays an annual dividend of $0.50 per share and has a dividend yield of 3.0%. GSK pays out 47.0% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 128.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, Takeda Pharmaceutical had 11 more articles in the media than GSK. MarketBeat recorded 16 mentions for Takeda Pharmaceutical and 5 mentions for GSK. Takeda Pharmaceutical's average media sentiment score of 0.12 beat GSK's score of 0.12 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Takeda Pharmaceutical	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral

GSK has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market.

15.7% of GSK shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 10.0% of GSK shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

GSK presently has a consensus price target of $53.00, indicating a potential upside of 5.39%. Given GSK's higher possible upside, equities research analysts clearly believe GSK is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	3 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.90
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

GSK beats Takeda Pharmaceutical on 14 of the 17 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to argenex?

argenex (NASDAQ:ARGX) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

argenex has higher earnings, but lower revenue than Takeda Pharmaceutical. argenex is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	11.31	$1.29B	$22.46	34.56
Takeda Pharmaceutical	$28.32B	1.86	$1.27B	$0.39	42.50

60.3% of argenex shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 2.4% of argenex shares are owned by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

argenex has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market.

In the previous week, Takeda Pharmaceutical had 3 more articles in the media than argenex. MarketBeat recorded 16 mentions for Takeda Pharmaceutical and 13 mentions for argenex. argenex's average media sentiment score of 0.93 beat Takeda Pharmaceutical's score of 0.12 indicating that argenex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral

argenex has a net margin of 31.31% compared to Takeda Pharmaceutical's net margin of 4.31%. argenex's return on equity of 33.28% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.31%	33.28%	28.16%
Takeda Pharmaceutical	4.31%	11.07%	5.49%

argenex currently has a consensus price target of $1,017.78, indicating a potential upside of 31.11%. Given argenex's stronger consensus rating and higher possible upside, equities research analysts clearly believe argenex is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

argenex beats Takeda Pharmaceutical on 15 of the 17 factors compared between the two stocks.

How does Takeda Pharmaceutical compare to Teva Pharmaceutical Industries?

Takeda Pharmaceutical (NYSE:TAK) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

Teva Pharmaceutical Industries has a consensus price target of $41.78, suggesting a potential upside of 22.59%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Takeda Pharmaceutical had 1 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 16 mentions for Takeda Pharmaceutical and 15 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 0.84 beat Takeda Pharmaceutical's score of 0.12 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Neutral
Teva Pharmaceutical Industries	8 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Takeda Pharmaceutical's net margin of 4.31%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.31%	11.07%	5.49%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

Takeda Pharmaceutical has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market.

Teva Pharmaceutical Industries has lower revenue, but higher earnings than Takeda Pharmaceutical. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	1.86	$1.27B	$0.39	42.50
Teva Pharmaceutical Industries	$17.26B	2.27	$1.41B	$1.33	25.62

Summary

Teva Pharmaceutical Industries beats Takeda Pharmaceutical on 14 of the 16 factors compared between the two stocks.

Get Takeda Pharmaceutical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TAK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TAK vs. The Competition

Export

Metric	Takeda Pharmaceutical	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$52.86B	$2.97B	$6.23B	$22.81B
Dividend Yield	3.03%	1.98%	2.80%	4.12%
P/E Ratio	9.66	17.22	20.66	29.86
Price / Sales	1.86	243.03	546.48	92.36
Price / Cash	5.35	56.35	27.48	18.80
Price / Book	1.03	3.93	9.67	4.59
Net Income	$1.27B	$74.99M	$3.56B	$1.07B
7 Day Performance	1.47%	-5.07%	-1.91%	-1.35%
1 Month Performance	-7.01%	-7.93%	-2.65%	-1.29%
1 Year Performance	17.51%	31.85%	31.17%	21.88%

Takeda Pharmaceutical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TAK Takeda Pharmaceutical	2.6928 of 5 stars	$16.58 -0.2%	N/A	+17.8%	$52.86B	$28.32B	42.50	47,455	Analyst Downgrade
NVO Novo Nordisk A/S	4.6486 of 5 stars	$46.34 +0.6%	$65.56 +41.5%	-30.5%	$205.70B	$46.80B	10.88	69,505	Analyst Upgrade
SNY Sanofi	4.3029 of 5 stars	$42.50 -1.9%	$51.00 +20.0%	-17.4%	$105.63B	$47.35B	11.87	74,846	Positive News
GSK GSK	3.3147 of 5 stars	$49.82 -1.2%	$53.00 +6.4%	+32.0%	$102.29B	$43.07B	12.95	66,841	Dividend Cut Ex-Dividend
ARGX argenex	4.7427 of 5 stars	$813.28 +4.0%	$1,017.78 +25.1%	+41.3%	$48.64B	$4.25B	36.21	1,863

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:TAK) was last updated on 5/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Takeda Pharmaceutical (TAK) Competitors

TAK vs. NVO, SNY, GSK, ARGX, and TEVA

How does Takeda Pharmaceutical compare to Novo Nordisk A/S?

Summary

How does Takeda Pharmaceutical compare to Sanofi?

Summary

How does Takeda Pharmaceutical compare to GSK?

Summary

How does Takeda Pharmaceutical compare to argenex?

Summary

How does Takeda Pharmaceutical compare to Teva Pharmaceutical Industries?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAK vs. The Competition

Takeda Pharmaceutical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Takeda Pharmaceutical (TAK) Competitors

TAK vs. NVO, SNY, GSK, ARGX, and TEVA

How does Takeda Pharmaceutical compare to Novo Nordisk A/S?

Which has more risk & volatility, TAK or NVO?

Does the media favor TAK or NVO?

Do insiders & institutionals have more ownership in TAK or NVO?

Is TAK or NVO more profitable?

Is TAK or NVO a better dividend stock?

Which has higher earnings and valuation, TAK or NVO?

Do analysts prefer TAK or NVO?

Summary

How does Takeda Pharmaceutical compare to Sanofi?

Do analysts prefer TAK or SNY?

Is TAK or SNY more profitable?

Do institutionals & insiders have more ownership in TAK or SNY?

Is TAK or SNY a better dividend stock?

Which has preferable valuation and earnings, TAK or SNY?

Which has more risk and volatility, TAK or SNY?

Does the media favor TAK or SNY?

Summary

How does Takeda Pharmaceutical compare to GSK?

Which has better earnings and valuation, GSK or TAK?

Is GSK or TAK more profitable?

Is GSK or TAK a better dividend stock?

Does the media favor GSK or TAK?

Which has more volatility and risk, GSK or TAK?

Do institutionals and insiders have more ownership in GSK or TAK?

Do analysts rate GSK or TAK?

Summary

How does Takeda Pharmaceutical compare to argenex?

Which has better earnings & valuation, ARGX or TAK?

Do insiders & institutionals have more ownership in ARGX or TAK?

Which has more volatility and risk, ARGX or TAK?

Does the media favor ARGX or TAK?

Is ARGX or TAK more profitable?

Do analysts rate ARGX or TAK?

Summary

How does Takeda Pharmaceutical compare to Teva Pharmaceutical Industries?

Do analysts recommend TAK or TEVA?

Do institutionals and insiders hold more shares of TAK or TEVA?

Does the media refer more to TAK or TEVA?

Is TAK or TEVA more profitable?

Which has more volatility and risk, TAK or TEVA?

Which has stronger valuation and earnings, TAK or TEVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAK vs. The Competition

Takeda Pharmaceutical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools